Besremi market seen growing on rising MPN diagnoses and longer-acting treatments

The Business Research Company says the Besremi market is poised for steady expansion through 2035, driven by rising diagnoses of myeloproliferative neoplasms, growing use of longer-acting interferons, and broader access to specialty hematology care. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Besremi is tied to treatment for polycythemia vera, a rare blood cancer within the myeloproliferative neoplasm category. - The market’s growth reflects broader demand for therapies that are more convenient, longer-acting and easier for patients to stay on over time. - A larger diagnosis pool for myeloproliferative neoplasms could expand use of Besremi and similar disease-modifying treatments.

What happened: - The Business Research Company published its Besremi Market Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Besremi market has gained momentum from unmet clinical needs in polycythemia vera, the drawbacks of traditional interferon therapies and rising adoption among hematology specialists. - The report is available as a free sample here. - The full report is available here.

The details: - Besremi, or ropeginterferon alfa-2b, is a long-acting interferon designed for polycythemia vera. - Pegylation technology extends the drug’s duration of action. - Once hematological stability is reached, dosing can move to biweekly or monthly schedules. - The report says the market should benefit from rising diagnosis rates of myeloproliferative neoplasms, greater access to specialized hematology care, better adherence and growing evidence on long-term outcomes. - Expected trends include longer-acting interferon treatments, more disease-modifying therapies for MPNs, wider use of reduced dosing frequencies and more use of specialty hematology clinics. - Besremi targets the bone marrow to reduce overproduction of red blood cells and help stabilize hematocrit, platelets and leukocytes. - The Leukemia & Lymphoma Society said in June 2023 that about 20,000 new MPN cases are diagnosed each year in the U.S. - The Leukemia & Lymphoma Society also said the UK sees about 4,180 new myeloproliferative cancer cases each year. - The report says North America held the largest Besremi market share in 2025 because of strong healthcare infrastructure and early adoption of innovative therapies. - The report projects Asia-Pacific will grow fastest, helped by higher healthcare investment, rising MPN awareness and better access to specialized treatment. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Between the lines: - The report points to a market shaped less by short-term drug sales dynamics and more by long-term shifts in diagnosis, specialist access and treatment adherence. - North America’s lead suggests the earliest market gains are concentrated in systems with strong specialty care networks. - Asia-Pacific’s growth outlook signals where future demand may accelerate as diagnostic and treatment access improves.

What's next: - The market outlook through 2035 depends on whether diagnosis rates keep rising and whether patients and physicians continue shifting toward longer-acting interferon options. - More use of specialty hematology clinics could become a key channel for adoption. - The Business Research Company invites direct contact through Saumya Sahay for more information and distribution details.